Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMOTION
2022-500185-94-01Phase 2Authorised
- Sponsor
- Mikrobiomik
- Start
- Feb 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing Allogeneic faecal microbiota capsules with Placebo capsules (2 arms). Primary endpoints: Histological NASH resolution without fibrosis worsening, No fibrosis or activity worsening and 2 more. Planned start Feb 2025; status: authorised.
02
Drugs
allogeneic faecal microbiota
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on 2022-500185-94-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500185-94-01.